Skip to main content

Advertisement

Table 2 Summary table on costs and utilities for HPV-related disease

From: Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy

HPV-related disease Cost (€) References Utility References
Females Males Males Females
CIN 1 452.0   [22]   0.8396 [22]
CIN 2 1485.0   [22]   0.7967 [22]
CIN 3, CIS 1971.8   [22]   0.8396 [22] (assumption on CIS)
Cervical cancer, local disease 20,652.7   [22]   0.54375 [22]
Cervical cancer, regional disease 35,930.4   [22]   0.5701 [22]
Cervical cancer, distant disease 34,574.7   [22]   0.4517 [22]
VaIN 2 3237.0   [22]   0.9793 [22]
VaIN 3, CIS 3237.0   [22]   0.9793 [22]
Vaginal cancer, local disease 7703.2   [22]   0.54375 [22]
Vaginal cancer, regional disease 19,835.9   [22]   0.5701 [22]
Vaginal cancer, distant disease 29,646.9   [22]   0.4517 [22]
Vulvar cancer, local disease 7183.7   [22]   0.54375 [22]
Vulvar cancer, regional disease 16,032.6   [22]   0.5701 [22]
Vulvar cancer, distant disease 20,365.4   [22]   0.4517 [22]
Penile cancer, local disease   10,497.6 [15] 0.7922   [22]
Penile cancer, regional disease   10,497.6 [15] 0.7922   [22]
Penile cancer, distant disease   10,497.6 [15] 0.7922   [22]
Anal cancer, local disease 9812.4 9812.4 [22] 0.653 0.69615 [22]
Anal cancer, regional disease 18,480.4 18,480.4 [22] 0.4175 0.5172 [22]
Anal cancer, distant disease 11,993.6 11,993.6 [22] 0.1998 0.2244 [22]
Head & Neck cancer, local disease 10,081.7 10,081.7 [22] 0.8171 0.7413 [22]
Head & Neck cancer, regional disease 28,572.1 28,572.1 [22] 0.5601 0.551 [22]
Head & Neck cancer, distant disease 28,572.1 28,572.1 [22] 0.5601 0.551 [22]
Genital warts 700.3 495.8 [15] 0.6961 0.7761 [22]
Recurrent respiratory papillomatosis 195,814.9 195,814.9 [15] 0.795698925 0.795698925 [53]